Cargando…

miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3(rd) Line Cetuximab and Irinotecan

INTRODUCTION: MicroRNAs (miRNAs) have important regulatory functions in cellular processes and have shown promising potential as prognostic markers for disease outcome in patients with cancer. The aim of the present study was to find miRNA expression profiles in whole blood that were prognostic for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schou, Jakob V., Rossi, Simona, Jensen, Benny V., Nielsen, Dorte L., Pfeiffer, Per, Høgdall, Estrid, Yilmaz, Mette, Tejpar, Sabine, Delorenzi, Mauro, Kruhøffer, Mogens, Johansen, Julia S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062472/ https://www.ncbi.nlm.nih.gov/pubmed/24940606 http://dx.doi.org/10.1371/journal.pone.0099886

Ejemplares similares

CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab
por: Skougaard, Kristin, et al.
Publicado: (2014)

Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer
por: Palshof, Jesper Andreas, et al.
Publicado: (2017)

Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing
por: Demuth, Christina, et al.
Publicado: (2018)

ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer
por: Palshof, Jesper Andreas, et al.
Publicado: (2020)

MicroRNA Expression in Formalin-fixed Paraffin-embedded Cancer Tissue: Identifying Reference MicroRNAs and Variability
por: Boisen, Mogens Karsbøl, et al.
Publicado: (2015)

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
por: Loupakis, F, et al.
Publicado: (2009)

Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer
por: Popovici, Vlad, et al.
Publicado: (2013)

Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)
por: Nakamura, Masato, et al.
Publicado: (2016)

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
por: Kim, Seung Tae, et al.
Publicado: (2015)

Phase II trial of biweekly cetuximab and irinotecan as third‐line therapy for pretreated KRAS exon 2 wild‐type colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2018)

SAT219 Severe Isolated Hypocalcemia With Cetuximab & Irinotecan Chemotherapy
por: Thomas, Melbin, et al.
Publicado: (2023)

Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08
por: Masuishi, Toshiki, et al.
Publicado: (2020)

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours
por: Segelov, Eva, et al.
Publicado: (2016)

Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab
por: Boisen, Mogens K., et al.
Publicado: (2014)

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010)

Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data
por: Buhl, Ida Kappel, et al.
Publicado: (2016)

The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC
por: Weidhaas, Joanne B., et al.
Publicado: (2023)

Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer
por: Siena, Salvatore, et al.
Publicado: (2013)

Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study
por: Burtness, Barbara, et al.
Publicado: (2016)

Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second‐Line Treatment for Patients with Metastatic Colorectal Cancer
por: Sobrero, Alberto, et al.
Publicado: (2020)

Identification of new biomarkers to promote personalised treatment of patients with inflammatory rheumatic disease: protocol for an open cohort study
por: Kringelbach, Tina Marie, et al.
Publicado: (2018)

A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy
por: Eng, Cathy, et al.
Publicado: (2016)

A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial
por: Saridaki, Z, et al.
Publicado: (2012)

EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
por: Spindler, Karen-Lise G, et al.
Publicado: (2011)

A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
por: Koo, Dong Hoe, et al.
Publicado: (2007)

Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations
por: Gollins, Simon, et al.
Publicado: (2017)

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
por: Hsu, Hung-Chih, et al.
Publicado: (2016)

Lymph-vascular space invasion (LVSI) as a strong and independent predictor for non-locoregional recurrences in endometrial cancer: a Danish Gynecological Cancer Group Study
por: Ørtoft, Gitte, et al.
Publicado: (2019)

Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review)
por: Sisman, Yagmur, et al.
Publicado: (2022)

Booster Operation Committee: Minutes of the 53rd Meeting (7.2.1979)
por: Schou, V
Publicado: (1979)

Next Generation Sequencing Technology in the Clinic and Its Challenges
por: Vestergaard, Lau K., et al.
Publicado: (2021)

Expression Stability Analysis of Candidate References for Normalization of RT-qPCR Data Using RefSeeker R package
por: Petersen, Patrick H.D., et al.
Publicado: (2023)

Identification of stably expressed microRNAs in plasma from high-grade serous ovarian carcinoma and benign tumor patients
por: Petersen, Patrick H.D., et al.
Publicado: (2023)

Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial
por: Vincenzi, B, et al.
Publicado: (2006)

Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer
por: Meyerhardt, Jeffrey A., et al.
Publicado: (2012)

Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial
por: Garufi, C, et al.
Publicado: (2010)

Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab
por: Giampieri, Riccardo, et al.
Publicado: (2015)

Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial
por: Lipsyc-Sharf, Marla, et al.
Publicado: (2022)

Cetuximab-Conjugated Magnetic Poly(Lactic-co-Glycolic Acid) Nanoparticles for Dual-Targeted Delivery of Irinotecan in Glioma Treatment
por: Dash, Banendu Sunder, et al.
Publicado: (2023)

The influence of insulin-related genetic variants on fetal growth, fetal blood flow, and placental weight in a prospective pregnancy cohort
por: Reim, Pauline K., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_auqnbqcnv3j5p6u5qfuu50htps